论文部分内容阅读
[目的]评价调脂治疗非酒精性脂肪肝(NAFLD)患者的疗效。[方法]选择2006年7月至2009年7月到枣庄市立医院健康查体确定为轻、中度NAFLD,但血脂水平分层标准在“合适范围”的患者100例,治疗组80例口服阿托伐他汀20 mg/d,疗程12周;对照组20例与治疗组均给予治疗性生活方式。连续观察12周。[结果]治疗12周与治疗前比较,治疗组血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)下降,高密度脂蛋白胆固醇(HDL-C)上升(P<0.01),对照组上述指标的差异均无统计学意义(P>0.05)。肝/脾CT比值,治疗组由0.70±0.23改善为0.91±0.25(P<0.01)。[结论]调脂治疗对于治疗非酒精性脂肪肝有明显的近期效果。
[Objective] To evaluate the efficacy of lipid-lowering therapy in patients with non-alcoholic fatty liver disease (NAFLD). [Methods] From July 2006 to July 2009 to Zaozhuang Municipal Hospital physical examination identified as mild to moderate NAFLD, but the level of stratified blood lipid level in the “appropriate range” of 100 patients, the treatment group of 80 patients Atorvastatin 20 mg / d was orally administered for 12 weeks, while 20 patients in the control group and the treatment group were given therapeutic lifestyle. Continuous observation of 12 weeks. [Results] The levels of serum total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), triglyceride (TG) and high density lipoprotein cholesterol (HDL-C) (P <0.01). There was no significant difference in the above indexes in the control group (P> 0.05). Liver / spleen CT ratio improved from 0.70 ± 0.23 to 0.91 ± 0.25 (P <0.01) in the treatment group. [Conclusion] Lipid-lowering treatment has obvious short-term effect on non-alcoholic fatty liver.